Eli Lilly Appoints Dr. Carole Ho and Promotes Adrienne Brown and Daniel Skovronsky in Leadership Restructure Focused on Neuroscience and Immunology

Eli Lilly and Company has announced changes to its leadership team, focusing on advancements in neuroscience and immunology. Dr. Carole Ho, formerly of Denali Therapeutics, has joined the company, while Adrienne Brown and Daniel Skovronsky have received promotions within the organization.

Dr. Ho brings expertise from her tenure at Denali Therapeutics, a biopharmaceutical company specializing in neurodegenerative diseases. Her appointment aligns with Eli Lilly’s strategic focus on neuroscience research and development. Additionally, Adrienne Brown and Daniel Skovronsky have been promoted to new roles within the company’s leadership structure. These moves reflect Eli Lilly’s ongoing commitment to strengthening its capabilities in both neuroscience and immunology as part of its broader organizational goals.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 7, 2025

Related posts:

Study Links Higher Screen Time to Differences in Attention Scores in Children Aged 3-7 Administration Policies and Patient Retention Challenges Shape Pharmaceutical Sector on July 8, 2025 Astellas Pharma Secures Conditional Approval in Japan for Izervay to Treat Geographic Atrophy GLP-1 Receptor Agonists May Affect FDG-PET-CT Cancer Detection by Altering Glucose Metabolism

Author

GOAI